Amandeep Salhotra, MD

Articles

Future Directions in Chronic GVHD Management

October 9th 2025

Panelists discuss how the future of chronic GVHD management looks promising with advances in graft manipulation strategies, expanded posttransplant cyclophosphamide use, dose optimization studies, oral CSF-1R inhibitors in development, and ongoing phase III trials studying current FDA-approved agents in earlier treatment lines and combination therapies to reduce patient morbidity and improve outcomes.

Insights Into Real-World Evidence in Chronic GVHD

October 9th 2025

Panelists discuss how real-world evidence shows lower response rates and shorter time to next treatment compared to clinical trials due to more advanced patient populations and different monitoring practices, while highlighting the potential value of combination therapies using multiple FDA-approved agents simultaneously despite the lack of formal trial data supporting such approaches.

Case 2: cGVHD With Ocular and Hepatic Involvement

October 2nd 2025

Panelists discuss how a 48-year-old female patient with chronic GVHD involving ocular, hepatic, and skin manifestations presents diagnostic challenges when elevated liver enzymes could indicate disease progression or drug toxicity from belumosudil and axicabtagene ciloleucel, leading to consideration of alternative treatments like mycophenolate or the preference for axicabtagene ciloleucel in patients with prior treatment failures or significant lung involvement despite the lack of head-to-head comparative data.

Treatment Sequencing and Organ-Based Considerations in Chronic GVHD

October 2nd 2025

Panelists discuss how treatment selection for multiorgan chronic GVHD currently relies on trial data, toxicity profiles, and practical considerations like proximity to treatment centers and patient preference for oral vs intravenous therapy, while looking toward future developments in predictive biomarkers that could enable personalized treatment selection and early preemptive intervention before clinical symptoms develop.

Assessment and Early Management After Steroid Failure in Chronic GVHD

September 25th 2025

Panelists discuss how the availability of novel agents has transformed chronic GVHD management by shortening steroid treatment duration to 2 to 3 weeks before adding second-line therapy, with response assessment focusing on dominant organ involvement rather than comprehensive National Institutes of Health criteria, and emphasizing patient-reported outcomes and quality of life measures as essential components of treatment evaluation in clinical practice.

Case 1: Multiorgan cGVHD With Pulmonary Involvement

September 25th 2025

Panelists discuss how a 52-year-old male patient developed multiorgan chronic GVHD 9 months post transplant with skin tightness, joint pain, and pulmonary involvement that showed minimal response to initial prednisone therapy and only moderate improvement after adding ruxolitinib, highlighting the importance of early detection through patient education and regular monitoring including spirometry to prevent irreversible fibrosis.

Novel Mechanisms and Emerging Therapies in Chronic GVHD

September 18th 2025

Panelists discuss how belumosudil works through anti-inflammatory and antifibrotic mechanisms by preventing actin filament polymerization and sequestering transcription factors, while axatilimab-csfr represents a novel approach targeting monocyte and macrophage pathways through CSF-1R blockade to reduce tissue inflammation and fibrosis in patients with chronic GVHD who have failed multiple prior therapies.

Advances in Prevention and Treatment Approvals in Chronic GVHD

September 18th 2025

Panelists discuss how recent FDA approvals of 4 agents (ibrutinib, ruxolitinib, belumosudil, and axatilimab-csfr) have expanded treatment options for chronic graft-vs-host disease, with each drug targeting different mechanisms including BTK inhibition, JAK1/JAK2 inhibition, and ROCK2 pathway modulation, while also noting significant advances in disease prevention strategies.

EBMT 2025: Exciting Updates and Advancements in AlloHSCT

June 18th 2025

Panelists discuss key updates from EBMT (European Society for Blood and Marrow Transplantation) 2025, including advancements in immune reconstitution, novel graft-vs-host disease (GVHD) prophylaxis strategies, and addressing ongoing unmet needs in allogeneic hematopoietic stem cell transplantation (alloHSCT), such as improved infection control, GVHD prevention, and enhancing long-term survival and quality of life.

Unanswered Questions and the Future for Orca-T: What’s Next?

June 18th 2025

Panelists discuss how unanswered questions regarding long-term outcomes and potential late toxicities, along with the need for further evaluation in specific patient subgroups, highlight the importance of continued research to refine the use of Orca-T across diverse populations.

Expert Perspectives: Orca-T Conditioning Regimens

June 11th 2025

Panelists discuss how Orca-T may expand patient eligibility for allogeneic hematopoietic stem cell transplantation (alloHSCT) by including those typically considered high-risk for traditional transplant due to its lower toxicity and improved safety profile, potentially broadening the pool of eligible patients.

Orca-T and the Future of AlloHSCT: Addressing Unmet Needs

June 11th 2025

Panelists discuss how Orca-T adds significant value to the allogeneic hematopoietic stem cell transplantation (alloHSCT) treatment landscape by reducing nonrelapse mortality and re-hospitalization rates, offering improved clinical outcomes and lower toxicity, thus enhancing patient recovery and quality of life posttransplant.

EBMT 2025 Highlight: Comparing Orca-T and PTCy – Insights From the Phase 1b Orca-T and Registry-Based PTCy Patients

June 4th 2025

Panelists discuss how the results of the phase 1b Orca-T trial, compared with registry-based patients who are posttransplant cyclophosphamide (PTCy), demonstrates improved response rates and progression-free survival with a favorable safety profile, suggesting Orca-T may offer better clinical outcomes than standard PTCy-based therapies.

EBMT 2025 Spotlight: Key Takeaways From the Orca-T Phase 3 Trial – Efficacy, Safety, and Insights

June 4th 2025

Panelists discuss how the Orca-T Phase 3 trial presented at EBMT (European Society for Blood and Marrow Transplantation) 2025 shows significant improvements in progression-free survival (PFS) and response rates compared with standard treatment, with manageable safety, highlighting its potential as a new treatment option pending further long-term studies.

Orca-T: A New Allogeneic Cell Therapy - Defining Orca-T and Potential Advantages Compared With Conventional AlloHSCT

May 28th 2025

Panelists discuss how Orca-T is a novel allogeneic cell therapy that reduces the risk of graft-vs-host disease (GVHD) by using T-cell-depleted grafts and a proprietary engineered approach, combined with single-agent tacrolimus to minimize immune suppression while preserving the graft-vs-leukemia effect.

Evolving GVHD Prophylaxis: Emerging Drug and Graft Engineering Strategies

May 28th 2025

Panelists discuss how advancing graft-vs-host disease (GVHD) management includes innovative strategies such as targeted therapies, graft engineering with regulatory T cells, optimization of posttransplant cyclophosphamide (PTCy), and the use of biomarkers for early detection, all aimed at improving GVHD prevention and treatment outcomes.

Identifying Appropriate Patients for PTCy as GVHD Prophylaxis in AlloHSCT

May 21st 2025

Panelists discuss how cautious use of posttransplant cyclophosphamide-based (PTCy) graft-vs-host disease (GVHD) prophylaxis may be considered in high-risk patients, certain donor types, or those with toxicity concerns, where more traditional regimens such as calcineurin inhibitors (CNIs) and methotrexate (MTX) may be preferred to balance GVHD prevention and minimize complications.

EBMT 2025 Highlight: Real-World GVHD Prophylaxis: - Insights From the GETH/TC Group Study

May 21st 2025

Panelists discuss how the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH/TC) real-world study highlights the effectiveness of posttransplant cyclophosphamide (PTCy)-based graft-vs-host disease (GVHD) prophylaxis in reducing acute GVHD incidence and treatment failure rates, supporting its adoption as a standard strategy, particularly in settings with limited donor availability.

EBMT 2025 Spotlight: Long-Term Outcomes With PTCy – Insights From the ALWP-EBMT

May 14th 2025

Panelists discuss how long-term outcomes following posttransplant cyclophosphamide (PTCy)-based graft-vs-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (alloHSCT) show promising survival rates but highlight the ongoing need for optimization in GVHD management and supportive care due to the higher incidence of chronic GVHD and nonrelapse mortality.

Managing GVHD: Incidence and Prophylaxis Strategies After AlloHSCT

May 14th 2025

Panelists discuss how graft-vs-host disease (GVHD) remains a significant complication in post-allogeneic hematopoietic stem cell transplantation (alloHSCT), with incidence rates varying by donor type and prophylaxis used, while emphasizing evolving prophylaxis practices and institutional variations in treatment approaches.